Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy GeoVax Labs stock in Canada

Own GeoVax Labs shares in just a few minutes.

GeoVax Labs is a biotechnology business based in the US. GeoVax Labs stocks (GOVX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.57 – a decrease of 18.9% over the previous week. GeoVax Labs employs 7 staff and has a trailing 12-month revenue of around $472,160.

How to buy shares in GeoVax Labs

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GOVX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy GeoVax Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted GeoVax Labs's stock price?

Since the stock market crash in March caused by coronavirus, GeoVax Labs's stock price has had significant positive movement.

Its last market close was $2.66, which is 93.61% up on its pre-crash value of $0.17 and 2,209.03% up on the lowest point reached during the March crash when the stocks fell as low as $0.1152.

If you had bought $1,000 worth of GeoVax Labs stocks at the start of February 2020, those stocks would have been worth $585.55 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $5,911.11.

GeoVax Labs stock price (NASDAQ:GOVX)

Use our graph to track the performance of GOVX stocks over time.

GeoVax Labs shares at a glance

Information last updated 2022-01-17.
Latest market close$2.66
52-week range$2.64 - $8.71
50-day moving average $3.84
200-day moving average $4.54
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.13

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

GeoVax Labs price performance over time

Historical closes compared with the close of $2.66 from 2022-01-18

1 week (2022-01-12) -18.90%
1 month (2021-12-17) -31.79%
3 months (2021-10-19) -33.50%
6 months (2021-07-19) -38.14%
1 year (2021-01-19) -38.99%
2 years (2020-01-17) 379,900.00%
3 years (2019-01-18) 9,572.73%
5 years (2017-01-19) 3,986.02%

GeoVax Labs financials

Revenue TTM $472,160
Gross profit TTM $-620,801
Return on assets TTM -26.33%
Return on equity TTM -42.78%
Profit margin 0%
Book value $2.82
Market capitalisation $17.7 million

TTM: trailing 12 months

GeoVax Labs share dividends

We're not expecting GeoVax Labs to pay a dividend over the next 12 months.

Have GeoVax Labs's shares ever split?

GeoVax Labs's shares were split on a 1:20 basis on 24 September 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GeoVax Labs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for GeoVax Labs shares which in turn could have impacted GeoVax Labs's share price.

GeoVax Labs share price volatility

Over the last 12 months, GeoVax Labs's shares have ranged in value from as little as $2.64 up to $8.71. A popular way to gauge a stock's volatility is its "beta".

GOVX.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GeoVax Labs's is 1.852. This would suggest that GeoVax Labs's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

GeoVax Labs overview

GeoVax Labs, Inc. , a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U. S. Department of Defense; U. S.

Stocks similar to GeoVax Labs

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site